How Do I Decide to Treat Patients with Geographic Atrophy?

Related

• 

  Preliminary Results from a First-in-human Phase I/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration

  Jared S. Nielsen, MD, MBA

  Updates from the Field

  2022

• 

  Vitreoretinal Interface Disease In the Setting of AMD

  Andrew A. Moshfeghi, MD, MBA, FASRS

  Updates from the Field

  2019

• 

  ARMD With Geographic Atrophy, Peripheral Degeneration

  James B. Soque, CRA, OCT-C, COA, FOPS

  Pamela Ann Weber, MD

  Retina Image Bank: Images of the Week

  2013